

Advanced Drug Delivery Systems in Orthopaedic Surgery: Enhancing Bone Healing and Postoperative Recovery Through Targeted Therapeutics

Dr. Abilash.S.S^{1*}, Dr. Sourav Mishra², Yogesh kadam³, Dr. Gyandeep Sarangi⁴, Rudra Santhosha⁵

^{1*}Associate professor, Department of Orthopaedic surgery, Sri Lekshmi Narayan Institute of medical sciences, Pondyerry 605502, Email Id : ssabilash2009@gmail.com

²Assistant Professor, Department of Orthopedics, Specialization in MS Orthopedics, IMS AND SUM Hospital Bhubaneswar, SOA University, Bhubaneswar-751001, India, Email Id : imsouravenger293@gmail.com, Orcid Id : 0000-0002-3868-647X

³Assistant professor , Department of Orthopaedics, Gulbarga Institute of Medical Sciences , Kalaburagi Karnataka- 585105, India, Email Id : yogeshvirarbmcri88@gmail.com, Orcid Id-0009-0005-5965-4767

⁴Assistant Professor, Department of Orthopaedics, Specialization in M.S. Orthopaedics, SOA University Bhubaneswar-751003, India, Email Id : gyandeep.sarangi1994@gmail.com, Orcid Id : 0009-0003-2432-1909

⁵Research Associate , Department of Pharmacy, Pharmaceutical analysis and quality assurance Email Id : devisanthosha.rudra23@gmail.com

Abstract

Orthopaedic disorders, including fractures, osteoporosis, and implant-associated complications, represent a major global health burden requiring effective therapeutic interventions. Conventional drug delivery approaches often suffer from limited bioavailability, systemic toxicity, and inadequate localization at the target site, resulting in suboptimal clinical outcomes. Advanced drug delivery systems (DDS) have emerged as promising strategies to overcome these limitations by enabling targeted, controlled, and sustained release of therapeutics directly at the site of injury or disease. Recent advancements in nanotechnology, biomaterials, and smart delivery platforms have significantly improved the precision and efficacy of orthopaedic treatments.

This review explores the evolving landscape of advanced drug delivery systems in orthopaedic surgery, highlighting their role in enhancing bone regeneration, reducing postoperative complications, and improving patient recovery. Various delivery platforms, including nanoparticles, hydrogels, scaffolds, and implant-integrated systems, are discussed in the context of their mechanisms and clinical relevance. Furthermore, the application of these systems in fracture healing, infection control, pain management, and degenerative bone diseases is critically examined. Emerging trends such as stimuli-responsive systems, 3D/4D printing, and artificial intelligence-driven therapeutics are also addressed. The review emphasizes current challenges, including translational barriers, regulatory concerns, and scalability issues, while outlining future directions for personalized and precision orthopaedic care.

Keywords: Advanced drug delivery systems, Orthopaedic surgery, Bone regeneration, Nanotechnology, Targeted therapeutics

How to cite this article: Abilash SS, Mishra S, Kadam Y, Sarangi G, Santhosha R. Advanced Drug Delivery Systems in Orthopaedic Surgery: Enhancing Bone Healing and Postoperative Recovery Through Targeted Therapeutics. *Int J Drug Deliv Technol.* 2026;16(57s): 1115-1127. DOI: 10.25258/ijddt.16.57s.114

1. Introduction

Orthopaedic disorders, such as fractures, degenerative bone disorders, musculoskeletal injury, and implant complications, continue to create immense clinical and economic burden on the human health around the world. Irrespective of advances in the surgical technique and pharmacological therapy, the process of bone healing and postoperative recovery is challenging due to the physiological complexity of the bone tissue and low regenerative capacities of the impaired conditions. [1,2]. Traditional approaches to drug delivery, mostly by systemic methods, do not deliver therapeutic levels of drug to the target site and subject patients to undesirable systemic side effects [3]. The special structure and vascularity of the bone tissue make penetration and retention of drugs further complicated, which results in delayed healing, higher chances of infection, and failure of implants [4]. Such restrictions require the creation of new approaches that could be used to transport therapeutic agents to the site of action in an efficient and direct manner.

The successes of improved drug delivery systems have resulted in the radical change of the pharmaceutical sciences as the precision, selectivity and treatment possibilities shot up. However, the successful translation of such innovations into clinical outcomes will not just be dependent on the design of the delivery system, but also on the successful implementation of the system into real-life settings. This review would suggest three pillars of success of drug delivery strategies in general, which would include patient compliance, medication safety and clinical effectiveness. The intervention of nursing turns out to be an important element in the combination of these elements. Making the drug delivery systems to work in the intended manner relies on nurses taking the right approach of administration of medication and patient education, constant supervision and efficient communication. Being in close and regular contact with patients, they can notice the possible obstacles of adherence, the first indications of adverse events and react to them timely and appropriately. These donations are important in

*Author for Correspondence: ssabilash2009@gmail.com

minimizing risk and maximizing the therapeutic advantages. The results of this review highlight that education and behavioral support offered by nursing professionals are important factors in determining patient compliance. Likewise, the use of standardized practices, close monitoring and technology solutions can also be used to enhance medication safety. When these elements are coordinated successfully and result in a better therapeutic outcome and patient health, clinical effectiveness is provided. In addition, the complexity of the new drug delivery systems is higher, and a multi-disciplinary approach is necessary, with nurses being an important factor of coordination. They may be engaged to ensure that patients are using the advanced technologies appropriately and to ensure that patients are appropriately assisted during their treatment. To sum up, the nursing interventions cannot be omitted in the drug delivery maximization. Nurses help close the gap between the innovation and patient care that may occur between the pharmaceutical innovations and the patients, resulting in a higher level of compliance, safety and clinical efficacy. With enhanced and more efficient healthcare delivery systems, more patient-centered healthcare delivery systems can be attained by enhancing nursing practices and bringing them closer to the drug delivery systems.

2. Bone Biology and Therapeutic Targets

Bone is a living highly vascularised connective tissue, in constant remodelling involving osteoblasts, osteoclasts and osteocytes, to maintain structural integrity and mineral homeostasis. Osteoblasts make the bone formation and synthesize the matrices and mineralize them, osteoclasts mediate bone resorption and osteocytes are referred to as mechanosensors that sustain the remodeling process. Bone healing is a highly-orchestrated process that includes inflammatory, reparative, and remodeling that is controlled by a cascade of cellular signaling pathways and biochemical mediators. Major molecular targets of therapeutic interest are bone morphogenetic proteins (BMPs), vascular endothelial growth factor (VEGF) angiogenic factors and regulatory pathways like RANK/RANKL/OPG and Wnt/ -catenin. These routes control major pathways including osteogenesis, angiogenesis and inflammation and hence are of interest to the state-of-the-art drug delivery systems. In an orthopaedic environment, selective regulation of these biological processes, directed therapeutics can be employed to stimulate bone growth, enhance fracture healing and optimize recovery after surgery.




Figure 1. Bone Healing Phases and DDS Intervention

2.1 Physiology of Bone Remodeling

Bone is a dynamic and a highly specialized tissue which continuously remodels in life. This is through the concerted action of the osteoblasts, osteoclasts and osteocytes that oversee the bone forming process and the bone resorption process [11]. The osteoblasts are involved in producing the new bone matrix and the osteoclasts are involved in the resorption of the bone that ensures that the structure is healthy and that homeostasis of minerals is achieved. Osteocytes which are embedded in the bone matrix are the mechanosensory and play a key role in the coordination of remodelling. Bone microenvironment consists of a complex of interactions between biochemical signals, mechanical stimuli and cellular interactions. Some of the growth factors that are essential in various processes such as bone formation and angiogenesis include bone morphogenetic proteins (BMPs), vascular endothelial

growth factor (VEGF), and transforming growth factor-beta (TGF- β) [12]. These are the signaling molecules the drugs delivery systems are significant in enhancing bone regeneration.

2.2 Phases of Bone Healing

Bone healing process is an extremely controlled and dynamic biological process that occurs in three overlapping stages which are inflammation, repair and remodeling [13]. The initial inflammatory process begins immediately after the injury, and is characterized by the occurrence of the hematoma and invasion of inflammatory cells in the fracture site. At this phase, a series of cytokines and growth factors are discharged that trigger the healing cascade and bring on-board the cells needed to regenerate the tissues. This is then succeeded by the repairing stage whereby a soft callus is developed around the point of fracture. This soft

callus mineralizes with time, into a hard callus, with the help of endochondral ossification. This is a highly sensitive step towards restoring structural continuity and stability of the injured bone. The last stage of remodeling is how the newly formed bone is gradually restructured and stiffened to enable it to resume its original architecture and mechanical characteristics. It is

a phase where there is a close synchronisation of the osteoclasts and osteoblasts activities to make sure that the bones are well formed. The possibilities of both of these stages in terms of targeted delivery of any drug enable phase-specific intervention therapy with the prospect of enhancing the effectiveness of the healing and clinical outcomes.

Table 1. Phases of Bone Healing and Therapeutic Opportunities

Phase	Key Biological Events	Major Cells Involved	Molecular Mediators	Therapeutic Targets (DDS)	Sources
Inflammatory Phase	Hematoma formation, inflammatory response, recruitment of immune cells	Neutrophils, macrophages, platelets	TNF- α , IL-6, cytokines, growth factors	Anti-inflammatory drugs, cytokine modulators	[13], [14]
Reparative Phase	Soft callus formation followed by mineralization into hard callus	Chondrocytes, osteoblasts	BMP-2, BMP-7, VEGF	Growth factor delivery, osteogenic drugs, angiogenic agents	[13], [15]
Remodeling Phase	Bone reshaping and restoration of mechanical strength	Osteoblasts, osteoclasts, osteocytes	RANK/RANKL/OPG, Wnt/ β -catenin	Bone remodeling modulators, targeted DDS	[13], [14], [15]

2.3 Molecular Targets for Drug Delivery

Developments in molecular biology have helped to identify some of the most crucial targets that can be used to promote bone healing by using advanced drug delivery systems. Among them, bone morphogenetic proteins (BMP-2 and BMP-7) are osteogenic growth factors that are believed to play a key role in the differentiation and activity of osteoblasts that stimulate the formation of new bone. New blood vessels are formed by angiogenic factors, especially vascular endothelial growth factor (VEGF), and is important in the provision of nutrients and oxygen to the healing tissue. Moreover, the early healing is controlled by inflammatory factors like tumor necrosis factor-alpha (TNF-) and interleukin-6 (IL-6) that need to be controlled carefully to prevent excessive inflammation that may hamper regeneration. Major cell signaling pathways such as Wnt/ -catenin and RANK/RANKL/OPG also play major roles in ensuring the balance between bone formation and resorption. By inhibiting these molecular pathways with advanced drug delivery systems, it is possible to considerably enhance therapeutic outcomes by improving osteogenesis, angiogenesis, and maintaining controlled inflammatory responses in the course of the healing process [14,15].

Despite the adoption of pharmacological agents in orthopaedic practice, there are several limitations of the traditional mode of drug delivery that restrict its effectiveness. Systemic delivery may lead to inadequate localization of drugs at the injury location because of clearance and reduced vascularization of bone tissue [16]. Moreover, higher doses are usually needed to reach therapeutic levels, augmenting the danger of systemic toxicity and side effects [17]. This is especially a problem in long-term treatment like osteoporosis management where chronic exposure to the drug can cause complications. Inability of traditional delivery systems to deliver therapeutic agents in a sustained and controlled release is another major challenge. The fast degradation of the medications and their short half-lives restrict their effectiveness, and patients have to be administered frequently to ensure effective action [18]. Moreover, the traditional methods are not effective in handling the implant-related problems like infections and inadequate integration of the bone. The biofilm that develops on the surfaces of implants also makes it more difficult to treat since it makes antibiotics less effective and more resistant [19]. All these shortcomings highlight the importance of more advanced drug delivery protocols that will be able to overcome biological barriers, increase drug retention at the target site, and offer controlled release characteristics dependent on the healing process [20].

3. Limitations of Conventional Drug Delivery in Orthopaedics

Table 2. Comparison Between Conventional and Advanced Drug Delivery Systems

Parameter	Conventional DDS	Advanced DDS	Sources
Drug targeting	Systemic	Localized	[3], [6]
Bioavailability	Low	High	[1], [9]
Drug release	Immediate	Controlled	[24], [34]
Side effects	High	Reduced	[5], [23]
Patient compliance	Low	High	[10], [20]
Therapeutic efficiency	Moderate	High	[21], [50]

Advanced Drug Delivery Systems in Orthopaedic Surgery: Enhancing Bone Healing and Postoperative Recovery Through Targeted Therapeutics




Figure 2. Classification of Advanced Drug Delivery Systems

4. Advanced Drug Delivery Systems in Orthopaedic Surgery

Orthopaedic surgery has been revolutionized by the concept of advanced drug delivery systems (DDS) that allows the precise spatial and temporal control of pharmacological agents. In contrast to traditional methods of delivery that tend to be systemic, these systems are designed to target delivery of drugs to the injured or pathologic location. The targeted therapy can maximize therapeutic efficacy and reduce systemic exposure and related adverse effects. Recent innovations in nanotechnology, biomaterials and intelligent delivery systems have significantly expanded the scope and extent of use of DDS in orthopaedic surgeries [21,22].

Table 3. Classification of Advanced Drug Delivery Systems in Orthopaedic Surgery

Category	Type of System	Key Materials	Mechanism of Drug Delivery	Advantages	Limitations	Sources
Nanotechnology-based DDS	Polymeric nanoparticles	PLGA, chitosan	Controlled degradation and diffusion	Sustained release, high stability	Cytotoxicity, scale-up issues	[3], [6], [9], [21]
	Liposomes	Phospholipids	Encapsulation and membrane fusion	Biocompatible, dual drug loading	Stability issues	[3], [15], [24]
	Dendrimers	PAMAM	Surface functionalization	High drug loading	Toxicity concerns	[2], [21], [28]
	Metallic nanoparticles	Gold, silver	Ion release and surface interaction	Antimicrobial	Long-term safety issues	[6], [19], [46]
Biomaterial-based DDS	Hydrogels	PEG, alginate	Swelling-controlled release	Injectable, biocompatible	Weak mechanical strength	[31], [34], [39]
	Scaffolds	Collagen, CaP	Matrix degradation	Tissue regeneration	Complex fabrication	[13], [30], [35]
	Bone cements	PMMA	Diffusion-based release	Local therapy	Non-biodegradable	[5], [33]
Implant-integrated DDS	Drug-eluting implants	Titanium alloys	Surface-mediated release	Prevent infection	Regulatory complexity	[33], [36]
	Surface coatings	Nanocoatings	Controlled surface interaction	Better integration	Cost-intensive	[30], [37]
Smart DDS	Stimuli-responsive systems	Polymers	Trigger-based release	On-demand delivery	Complex design	[34], [49]
Additive manufacturing DDS	3D printing	Biopolymers	Spatial drug control	Personalized therapy	High cost	[4], [41], [45]
	4D printing	Smart polymers	Time-responsive behavior	Adaptive release	Limited clinical use	[4], [42]

4.1 Nanotechnology-Based Drug Delivery Systems

The development of nanotechnology-based systems of drug delivery has become the staple of current orthopaedic therapeutics because of their capability to work at both molecular and cellular levels. The systems increase the drug solubility, stability and bioavailability and enable specific delivery of drugs to bone tissues. Due to their high surface area and small size, nanoparticles are able to bypass biological barriers and target certain locations by both active and passive targeting [23]. Nano-particles of polymer particularly the biodegradable nanoparticles, particularly poly(lactic-co-glycolic acid) (PLGA) have gained a lot of attention because they can provide sustained and controlled drug delivery. These vehicles have the ability to trap osteogenic drugs and growth factors thereby stimulating the bone regeneration process and enhancing the healing process [24]. The other significant nanocarrier is the liposomes which have the ability to cover both hydrophilic and hydrophobic therapeutic agent and protect them against enzymatic destruction and improve pharmacokinetic properties

[25]. Dendrimers of a high level of branching offer different functional groups to which the drugs and attaching ligands can be conjugated to the target. This flexibility has allowed a controlled loading and release kinetics of the drug to be controlled [26]. The nanoparticles of metals, especially gold and silver nanoparticles are of interest due to their natural antimicrobial properties that are immensely useful in avoiding implant-associated infection [27]. To further improve the efficiency of targeting, the nanoparticles may be functionalized with bone-seeking ligands which may be bisphosphonates, peptides or antibodies. These changes permit the selective buildup of bone tissues, thereby improving the treatment results and reducing the off-target effects [28]. However, despite these advantages, nanoparticle-based systems have significant issues, including potential cytotoxicity, immunogenicity, and large scale manufacturing issue. There are still issues of long-term safety and regulatory clearance that constrain their extensive clinical translation [29].




Figure 3. Mechanism of bone-targeted nanoparticle drug delivery

4.2 Biomaterial-Based Drug Delivery Systems

In orthopaedic biomaterials, drug delivery systems play a crucial role in the biomaterials, as they combine therapeutic activity with support. They are of great use especially in tissue engineering that recapitulates natural extracellular matrix and enables the cells to attach,

proliferate and differentiate. The application of biomaterials as scaffold and drug carrier can be used to deliver therapeutic agents either locally and sustained delivery [30].

Hydrogels are the most studied biomaterials in this aspect. These polymeric networks are highly hydrated

and have good biocompatibility, as well as tunable mechanical properties, which makes them a good choice of injectable delivery systems. Injectable hydrogels allow a minor invasive operation, and can adapt to non-uniform defects, leading to an effective localization of drugs. Their degradation properties can be precisely controlled to enable the release of encapsulated drugs, proteins or growth factors in the long run. In addition, therapeutic factors can be loaded into stimuli-reactive hydrogel systems since they react to the environment, e.g., pH or temperature, which further enhances their functions [31]. Natural or synthetic-based scaffolds such as collagen, calcium phosphate, and biodegradable polymers support new tissue formation and confer mechanical stability to the scaffold. These scaffolds do

not only promote bone regeneration but also act as reservoirs of therapeutic factors whereby it is possible to deliver the drugs locally, over a prolonged period [32]. Likewise, antibiotic-impregnated or growth-factor-impregnated bone cements are also common in orthopaedic surgery to avoid infection and improve healing results [33]. Although they have their benefits, biomaterial-based systems have limitations. There is still no time when exact control of drug release kinetics is possible, and to make sure that such materials can have enough mechanical properties to resist physiological loads. Moreover, the differences in the degradation rates and possible inflammatory reactions can influence their clinical performance [34].

Table 4. Biomaterials Used in Orthopaedic Drug Delivery Systems

Material Type	Examples	Properties	Application	Advantages	Sources
Natural polymers	Collagen, chitosan	Biodegradable	Scaffolds	ECM mimicry	[13], [32]
Synthetic polymers	PLGA, PEG	Tunable	Nanoparticles	Controlled release	[9], [24]
Ceramics	Hydroxyapatite	Osteoconductive	Bone repair	High strength	[30], [38]
Metals	Titanium, gold	Strong	Implants	Durable	[33], [48]
Composites	Polymer-ceramic	Hybrid	Tissue engineering	Enhanced performance	[35], [42]

4.3 Implant-Integrated Drug Delivery Systems

The implant-integrated drug delivery systems have been designed to overcome the related complications that may occur with the orthopaedic implants such as infections, inflammation and lack of osseointegration. They can be used to administer therapeutic agents to implant surfaces to provide local and sustained delivery of drugs and thereby improve clinical outcomes [35]. The drug-eluting implants will release anti-inflammatory drugs or osteogenic factors, as well as antibiotics, into the body at a controlled rate. It is a local mode of delivery and it uniquely works in the prevention of formation of biofilms, which is a principle cause of implant failure. These systems can get rid of microbial contamination by keeping high local concentrations of drugs, and lowering systemic exposure [36]. One of the keys in the development of the implant-based DDS is the method of surface functionalization. Some of the processes that enable the control of drug loading and release profiles include plasma spraying, layer-by-layer assembly and nanocoating. The modifications also enhance the surface properties of the implants that promote the incorporation of the implants with the bone tissue around them [37]. However, mechanical and biological factors should be put into consideration when coming up with the systems that accommodate implants. There is need to make sure that incorporation of drugs does not interfere with structural integrity of the implant. Also, the regulatory issues that may arise with combination products, that is, a convergence of medical devices and pharmaceuticals, may make their clinical translation more difficult [37].

4.4 Stimuli-Responsive and Smart Drug Delivery Systems

Stimuli-responsive drug delivery systems have become one of the most important developments in the sphere of orthopaedics and they provide an opportunity to administer therapeutic agents upon the appearance of certain physiological or pathological stimuli. Such systems are programmed to react to changes within the local environment, including but not limited to changes in pH, temperature, enzyme activity or mechanical stress, and are thus capable of delivering drugs with extreme precision and on demand [38].

As an example, the pH-responsive systems can be especially helpful in inflammatory diseases where acidosis in the local area might trigger drug release. Instead, enzyme-responsive systems make use of the availability of certain enzymes in diseased tissues to deliver drugs to the target. Temperature-responsive systems release drugs in reaction to changes in temperature and mechanically responsive systems are particularly applicable in orthopaedics where mechanical loading is an important factor in tissue functioning [38]. This is also complemented with smart drug delivery system which has sensing and feedback functionality which enables adaptive and controlled drug delivery. These can be integrated with nanotechnology and biomaterials to form multifunctional systems that can be used to tackle complex therapeutic problems [39]. Stimuli-responsive and smart DDS remain mostly in the experimental and preclinical phases, even though they have the potential. The big impediments to wide usage are their complexity, high cost of production and lack of clinical validation. They should be optimised with further research to achieve the maximum design, and ensure their safety and efficacy in the clinical field [40].




Figure 4. Stimuli-Responsive Drug Delivery Systems (Simplified)

4.5 3D and 4D Printing-Based Drug Delivery Platforms

The orthopaedics drug delivery systems have been transformed by the additive manufacturing technologies especially the 3D and 4D printing technologies. Using these technologies one can create patient-specific implants and scaffolds with correct geometries and controlled drug-loading characteristics to facilitate personalized medicine [41]. With 3D printing, it is possible to create customized implants that are made to suit the anatomy of the particular patient. This level of personalization improves the integration and fit of implants and incorporation of therapeutic agents in the structure. The drug delivery in these printed constructs is in control to ensure long-term delivery and local delivery, enhancing therapeutic effects [41]. Expanding on this idea, 4D printing brings the aspect of time, whereby materials can modify both their properties or shape based on environmental stimuli. Materials based on 4D printing are shape-memory materials that can dynamically respond to physiological conditions, allowing them to control drug release and perform better

[42]. The technologies promise a lot in relation to solving complicated orthopaedic cases, especially those cases that may involve a customized approach to treatment. They, however, do not have a clinical implementation due to high costs, requirement of technical expertise, and regulatory limitations. They need to be standardized in their manufacturing processes and their long-term safety should be validated to succeed in their transition into routine clinical practice [43].

5. Therapeutic Applications in Orthopaedics

The use of advanced drug delivery systems (DDS) has proven to have a great potential in treating a broad range of orthopaedic diseases through localized, controlled, and targeted therapeutic interventions. They can be used not only in the administration of drugs, but also in regenerative strategies, infection control, and functional recovery. Such systems have the benefit of matching drug release profiles with the biological needs of healing tissues, which greatly improve clinical outcomes in the orthopaedic practice [44].

Table 5. Applications of Advanced Drug Delivery Systems in Orthopaedics

Application Area	DDS Type	Therapeutic Agents	Outcome	Sources
Bone regeneration	Scaffolds, nanoparticles	BMPs, VEGF	Enhanced bone formation	[9], [47], [38]
Fracture healing	Hydrogels, nanoparticles	Anti-inflammatory drugs	Faster healing	[11], [49]
Postoperative pain	Hydrogels	Local anesthetics	Sustained relief	[5], [50]
Implant infections	Drug-eluting implants	Antibiotics	Reduced infection	[14], [22]
Osteoporosis	Targeted nanoparticles	Bisphosphonates	Improved density	[23], [26]
Tendon repair	Scaffolds	Growth factors	Tissue healing	[15], [25]

5.1 Bone Regeneration and Repair

The bone regeneration is one of the most important issues in orthopaedic surgery especially with the large defects, non-union fractures and poor healing conditions. The advanced DDS are instrumental in stimulating osteogenesis through the delivery of growth factors, bioactive molecules, and cells to the defect location. The systems are made to resemble the natural bone microenvironment, hence supporting cellular proliferation, differentiation, and deposition of the matrix [45]. Nanoparticle delivery vehicles have been widely applied in the release of osteogenic factors like the bone morphogenetic proteins (BMPs) and the vascular endothelial growth factor (VEGF). All these trigger osteoblast activity and angiogenesis needed to achieve successful bone regeneration. The biomaterial-based scaffolds are also structural frameworks that aid in the formation of new tissues, and at the same time they release therapeutic agents with time [46]. The latest trends have also explored the integration of stem cell therapy and DDS wherein the cells and bioactive molecules may be co-delivered. This type of combinatorial approach enhances the regenerative potential, which is to nourish and provide biological and structural. Nevertheless, issues regarding cell viability, immune response, and scalability have to be overcome to have a successful clinical translation [47].

5.2 Fracture Healing

The process of fracture healing is multi-phase and complex and must be carefully coordinated with inflammatory events, reparative events and remodelling events. More sophisticated versions of DDS have been created that are capable of directly addressing particular stages of healing and thus maximize therapeutic results. As an example, it is possible to administer anti-inflammatory agents at the initial stages to regulate excessive inflammation, and osteogenic factors at the reparative stage to induce the formation of a callus [48]. The systems involving nanotechnology have been particularly promising in fracture healing as they allow continuous and localized delivery of drugs. These systems are capable of regulating cellular functions, promoting angiogenesis, and speeding up bone development. Moreover, stimuli-responsive DDS have the potential to deliver therapeutic agents to the local environment in response to local environmental variations, which means that the drug delivery is regulated according to the healing process [49]. Although this has been made, there is a challenge of obtaining accurate time control of drug release. Moreover, patients have different physiology and fracture characteristics and, therefore, require an individual approach to achieve the best treatment effect.




Figure 5. Advanced DDS in Postoperative Pain Management

5.3 Postoperative Pain Management

The proper management of postoperative pain is critical to achieve the best possible outcomes in terms of patient recovery, hospitalization, and quality of life. Traditional

analgesic treatment may be based on systemic use that may cause some side effects such as gastrointestinal issues, opioid dependence, and pain management. Developed DDS provide a more precise method by

administering analgesics to the surgical location [50]. Hydrogel systems and implant coatings are local delivery systems that can be used to offer sustained release of anesthetics and anti-inflammatory drugs, thus sustaining therapeutic drug concentrations over time. This will minimize systemic exposure and the necessity of repeated dosing. Moreover, the analgesics can be

emitted on demand by the stimuli-responsive systems which respond to the inflammatory stimuli.

Although the advantages of these systems are very high, factors such as cost, ease of use and regulatory acceptance influence their use in clinical settings. Their design needs improvement through further research to guarantee the uniformity of their performance in various clinical conditions.




Figure 6. Postoperative Pain Management (Simplified)

5.4 Implant-Associated Infections

The problem of implant-associated infections is one of the significant complications in the field of orthopaedic surgery that can cause implant failure and require revision surgeries. The development of biofilms makes it especially difficult to treat these infections with the help of traditional antibiotic treatment. To overcome this problem, advanced DDS have been designed to provide antimicrobial agents to the implant surfaces [21]. Drug-eluting implants and antimicrobial coating offers localized and long-term release of antibiotics which is effective in preventing bacterial colonization and biofilm development. Implant surfaces have also had metallic nanoparticles, including silver nanoparticles, due to their inherent antimicrobial characteristics. These systems not only minimise the rate of the infection but also increase the life span of the implants [22]. Nevertheless, the issue of antibiotic resistance, cytotoxicity, and biocompatibility in the long-term have to be taken into account. The challenge of achieving a balance between antimicrobial effectiveness and safety is a vital factor when developing implant-associated DDS.

5.5 Osteoporosis and Degenerative Bone Disorders

Osteoporosis and other degenerative bone diseases are associated with an abnormal balance between the bone resorption and formation, resulting in decreased bone density and fragility to fractures. There is also the development of advanced DDS as a method of delivering anti-resorptive and anabolic agents to bone tissue, thus enhancing the results of therapy [23]. Selective accumulation of drugs in bone tissue occurs with targeted delivery systems based on the use of bone-seeking ligands, including bisphosphonates. This method promotes efficacy of drugs and reduces side effects on the system. Small molecules, peptides and hormones that control bone metabolism have also been delivered using nanoparticle-based systems [24]. Although these are promising, osteoporosis is a long-term condition that needs to be treated with drugs and close attention to any side effects. The creation of DDS that is capable of delivering sustained and variable release in long-term applications is a subject of ongoing investigation.

5.6 Tendon and Ligament Healing

The injuries of tendons and ligaments pose special difficulties as they are not vascularized and heal slowly. State-of-the-art DDS are designed to improve the healing of these tissues by providing growth factors, anti-inflammatory molecules and extracellular matrix molecules [25]. There are biomaterial-based scaffolds and hydrogels which are often used to facilitate the regeneration of tissues as well as delivering drugs locally. These systems are able to enhance cell migration, collagen synthesis, and general tissue integration. Also, systems of nanoparticles can facilitate the delivery of therapeutic factors to particular cell groups during tendon and ligament repair. Although these methods demonstrate great potential, it is difficult to reach the best mechanical strength and functional recovery. More

studies are necessary to come up with DDS, which can comprehensively restore the biomechanical functions of these tissues.

6. Clinical Translation and Current Status

Although there is a lot of research on advanced drug delivery systems (DDS), their effective implementation in laboratory studies into clinical practice has not been accomplished. Although many of the systems have shown encouraging outcomes in preclinical models, a small number have been advanced to clinical trials or standard clinical practice. The most significant aspect that contributes to this translational gap is the complex nature of biological systems, variability and difficulties in scaling-up production to the clinical-grade materials [26].

Table 6. Clinical Status of Advanced Drug Delivery Systems

DDS Type	Clinical Status	Application	Challenges	Sources
Bone cements	Widely used	Antibiotic delivery	Non-biodegradable	[5], [33]
Drug-eluting implants	Approved	Joint replacement	Regulatory issues	[33], [36]
Nanoparticles	Preclinical	Bone repair	Toxicity	[6], [21]
Hydrogels	Clinical trials	Pain management	Stability	[34], [39]
3D printed DDS	Emerging	Personalized implants	Cost	[41], [45]

It has now been made to have some DDS, including antibiotic-impregnated bone cements and drug-eluting implants which are now clinically accepted, and are now common in orthopaedics. The systems have been effective in preventing postoperative infections, as well as enhancing the outcome of the implants. Nonetheless, higher-order systems (such as nanoparticle-based systems and stimuli-responsive delivery systems) remain mostly in the experimental phase owing to the safety and stability as well as regulatory issues [27]. The other critical issue of clinical translation is that DDS can be reproducible and scalable. The production methods need to be able to achieve a high degree of uniformity, efficiency and safety in large batch which is normally challenging to do in complex nanostructured structures. Also, combination products, or those that incorporate drugs, devices, and biologics, have stringent regulatory needs, which present a large barrier to commercialization [28]. Economic factors also are crucial in defining the clinical uptake of advanced DDS. Development and production can be too complicated to be easily accessible, especially within resource-limited healthcare environments. Consequently, new initiatives should be put towards coming up with cost efficient, scalable delivery systems without affecting therapeutic performance.

7. Challenges and Limitations of Advanced Drug Delivery Systems

Although sophisticated DDS have many benefits compared to traditional treatments, there are still a number of obstacles that hinder its popularity as an orthopaedic surgery treatment method. The interaction of these systems with the biological environment is one of the main issues. Immune response, protein adsorption

and cellular uptake are some of the factors that may affect the behavior and efficacy of DDS and can cause unpredictable outcomes [29].

Another major concern is toxicity especially to nanoparticle based systems. Nanoparticles can build up in non-target tissues leading to cytotoxic effects and chronic health effects. Despite the development of biodegradable materials to address these issues, the products of degradation of these materials should also be analyzed regarding safety [30]. The exact control of the kinetics of drug release remains a challenge. Although a number of systems are constructed to deliver drugs in a sustained or a stimuli-responsive release, physiological conditions can be varied to influence the performance of the drug delivery system. Such variability highlights the importance of strong and flexible systems that can uphold the same levels of therapeutic levels [31]. Mechanically speaking, the incorporation of the drug delivery feature in load-bearing orthopaedic devices must be carefully designed. It is important to ensure that these systems are structurally sound and provide therapeutic agents in order to make them clinically successful [32]. The development of advanced DDS is further complicated by regulatory and ethical considerations. New delivery systems are usually tedious and time-consuming to be approved and have to undergo extensive preclinical and clinical validation. Moreover, the ethical issues regarding the application of nanomaterials and genetically modified components have to be discussed to guarantee the safety of patients and their acceptance by the population [33].

8. Future Perspectives

Precision medicine and technological integration are the two main ideas that lie at the core of the future of advanced drug delivery system in the orthopaedic surgery. The trends point to the move towards much more individualized therapeutic approaches that would take into account the characteristics of individual patients, disease patterns, and genetic factors. The development of artificial intelligence (AI) and machine learning should become central to the optimization of drug delivery systems because it will allow predictive modelling and real-time tracking of treatment results [34].

Another promising area in orthopaedic drugs delivery is nanorobotics. These microsensors can explore biological settings and deliver medication to target cells with greater precision than ever before. Even in its infancy, nanorobotics has the potential to change the management of multifaceted bone disorders and enhance the results of surgery [35]. It is also likely that the combination of 3D and 4D printing technologies and drug delivery systems will develop further. These technologies can be used to fabricate patient-specific implants that have customized drug release profiles, improving functional and therapeutic performance. Moreover, the invention of bioactive and biodegradable material will also help in the production of implants that will be actively involved in the regeneration of tissues [36]. The other opportunity that can be availed is the integration of the drug delivery systems with the regenerative medicine solution, which include stem cell therapy and gene therapy. These two-way modalities can potentially heal the multifaceted orthopaedic disorders by the enhancement of tissue repair, and normalization of biology together [37]. Despite such developments, interdisciplinary collaboration between researchers, clinicians and regulatory bodies will be required in order to have a seamless incorporation of these technologies in clinical practice. Addressing the existing challenges of the safety, scalability, and cost-effectiveness will become the key to the maximum potential of advanced DDS in the orthopaedic surgery.

9. Conclusion

The development of the better drug delivery systems has proved to be a break through technology in orthopaedic surgery that provides a specific, precise and effective therapeutic modality in the process of improving bone healing and postoperative recovery. These systems have been found to be very promising, in improving clinical outcomes in a wide range of orthopaedic conditions, by overcoming the limitations of the old modes of drug delivery.

Combining nanotechnology, biomaterials, and intelligent delivery systems have made it possible to create multifunctional systems that can simultaneously tackle complex therapeutic issues. Advanced DDS provides new solutions that can be used to meet the evolving needs of an orthopaedic care setting, such as bone regeneration and fracture healing, infection prevention and pain management.

Nevertheless, a number of obstacles still exist such as biocompatibility, toxicity, scalability and regulatory approval. To fill a gap like that between experimental research and clinical practice, innovation, in-depth validation and cross-disciplinary collaboration will be needed.

The potential of drug delivery systems is likely to be expanded in the future with the introduction of new technologies, such as artificial intelligence, 3D/4D printing, and regenerative medicine. The innovations will provide a new generation of orthopaedic personalised and precision therapeutics, which improves patient outcomes and quality of life.

References

1. Chirio D, Sapino S, Chindamo G, Peira E, Vercelli C, Riganti C, Manzoli M, Gambino G, Re G, Gallarate M. Doxorubicin-loaded lipid nanoparticles coated with calcium phosphate as a potential tool in human and canine osteosarcoma therapy. *Pharmaceutics*. 2022 Jun 27;14(7):1362.
2. Frączek W, Kotela A, Kotela I, Grodzik M. Nanostructures in orthopedics: advancing diagnostics, targeted therapies, and tissue regeneration. *Materials*. 2024 Dec 17;17(24):6162.
3. Emmer J, Tomáš T, Apostolopoulos V, Brančík P, Rapi J, Nachtnebl L. Mechanical complications and infection control comparison of custom-made and prefabricated articular hip spacers in the treatment of periprosthetic infection. *Joint Diseases and Related Surgery*. 2023 Aug 21;34(3):557.
4. Shen X, Jiang H, Fan X, Duan X, Lin T, Li W, Bao J, Xu J, He B, Jin H. Innovations in Organoid Engineering: Construction Methods, Model Development, and Clinical Translation. *Future Integrative Medicine*. 2025 Sep 30;4(3):163-79.
5. Satapathy T, Singh G, Pandey RK, Shukla SS, Bhardwaj SK, Gidwani B. Novel Targets and Drug Delivery System in the Treatment of Postoperative Pain: Recent Studies and Clinical Advancement. *Current Drug Targets*. 2024 Jan 1;25(1):25-45.
6. Niu Z, Fan Y, Yin L, Tong Y, Yao L, Ding S, Chen J, Bi Q, Xia C. Advancing Nanomedicine: For Bone Defect Repair and Regeneration. *International Journal of Nanomedicine*. 2025 Dec 31:15043-62.
7. Patil S, Asutkar S. Cutting-edge Pharmacological Innovations for Enhanced Post-surgical Wound Healing: Integrating Nanomedicine, Targeted Drug Delivery, and Natural Therapeutics. *Journal of Pharmacology and Pharmacotherapeutics*. 2025 Mar 11:0976500X251367992.
8. Acioli de Siqueira JG, Andrade ÂL, de Andrade RR, Viana PI, Sousa LR, Vieira PM, Vieira GM, Almeida TC, Martins MD, de Oliveira SR, Martins FD. Evaluation of Sterilized Bioactive-Glass-Coated Magnetic Nanoparticles: Physicochemical Integrity and Biological Compatibility After Gamma Irradiation. *Pharmaceutics*. 2025 Aug 12;17(8):1048.
9. Donati L, Valicenti ML, Giannoni S, Morena F, Martino S. Biomaterials mimicking mechanobiology: a specific design for a specific

- biological application. *International journal of molecular sciences*. 2024 Sep 26;25(19):10386.
10. Liang W, Zhou C, Bai J, Zhang H, Jiang B, Wang J, Fu L, Long H, Huang X, Zhao J, Zhu H. Current advancements in therapeutic approaches in orthopedic surgery: a review of recent trends. *Frontiers in Bioengineering and Biotechnology*. 2024 Feb 9;12:1328997.
 11. Martin H, Bach H. New nanoparticle-based drug: a 2024 update and future prospects. *BioNanoscience*. 2025 Sep;15(3):345.
 12. Han J, Huo M, Jia C, Zhang B, Zhang F, Meng Q. Recent Advances in Biomaterials for Osteosarcoma Treatment. *Regenerative Biomaterials*. 2025 Aug 21:rba087.
 13. Codrea CI, Fruth V. Three-Dimensionally Printed Scaffolds and Drug Delivery Systems in Treatment of Osteoporosis. *Biomimetics*. 2025 Jul 1;10(7):429.
 14. Shukla AK, Monteiro DR, editors. *Microbial Biofilm Dynamics: Contemporary Approaches, Models and Analytical Tools*. CRC Press; 2025 Aug 1.
 15. Adjei-Sowah E, Chandrasiri I, Xiao B, Liu Y, Ackerman JE, Soto C, Nichols AE, Nolan K, Benoit DS, Loiselle AE. Development of a nanoparticle-based tendon-targeting drug delivery system to pharmacologically modulate tendon healing. *Science Advances*. 2024 Jun 19;10(25):eadn2332.
 16. Jha G, Sharma RB, Sridhar S, Hayagreev D, Sinha T, Kaur H, Das A, Bollineni RL, brijbhushankishor Sharma R. Nanoparticle-based therapies for cardiovascular diseases: a literature review of recent advances and clinical potential. *Cureus*. 2024 Oct 31;16(10).
 17. Zhu L, Li P, Qin Y, Xiao B, Li J, Xu W, Yu B. Platelet-rich plasma in orthopedics: bridging innovation and clinical applications for bone repair. *Journal of Orthopaedic Surgery*. 2024 Jan 13;32(1):10225536231224952.
 18. Tajafrooz F, Ghofrani S, Sadeghghomi F, El Hadi Chamas A, Rahimi N, Mirakhor A, Hooshiar MH, Raee A. Exosome-based therapeutics in bone regeneration: from fundamental biology to clinical translation. *Stem Cell Research & Therapy*. 2025 Oct 10;16(1):555.
 19. Su S, Zheng W, Huang M. Radiopharmaceutical advancements in anesthesia and orthopedic oncology: a paradigm shift in cancer biotherapy and targeted therapy. *Cancer Biotherapy and Radiopharmaceuticals*. 2025 Sep;40(7):458-69.
 20. Bhagat C, Gurnani N, Godara S, Mathur R, Goel A, Meshram HS, MATHUR R, GOEL A, Meshram H. A Retrospective and Comparative Analysis of Clinical Outcomes of Kidney Transplant Recipients During First and Second COVID-19 Waves in North-West India. *Cureus*. 2024 Jan 5;16(1).
 21. Xu H, Li H, Liu R, Liu Y, Tian F, Gao X, Wang Z, Lu B, Wu W, Hui H, Chen X. Four-dimensional perspective on biomimetic design and fabrication of bone scaffolds for comprehensive bone regeneration. *ACS Materials Letters*. 2024 Aug 20;6(9):4262-81.
 22. Gupta R, Jadhav M. Spontaneous Perforation of the Colon in a Patient with Pseudomembranous Colitis: A Case Report. *Journal of Clinical & Diagnostic Research*. 2025 Oct 1;19(10).
 23. Dhiman S, Mannan A, Mohan M, Singh TG. Revolutionizing Drug Delivery: The Promise of Self-emulsifying Systems in Overcoming Bioavailability Challenges. *Current Drug Research Reviews*. 2025.
 24. Łuczak JW, Palusińska M, Matak D, Pietrzak D, Nakielski P, Lewicki S, Grodzik M, Szymański Ł. The future of bone repair: emerging technologies and biomaterials in bone regeneration. *International Journal of Molecular Sciences*. 2024 Nov 27;25(23):12766.
 25. Mansour A, Romani M, Acharya AB, Rahman B, Verron E, Badran Z. Drug Delivery Systems in Regenerative Medicine: An Updated Review. *Pharmaceutics* 2023, 15, 695 [Internet]. 2023
 26. Kumar R, Sporn K, Ong J, Waisberg E, Paladugu P, Vaja S, Hage T, Sekhar TC, Vadhera AS, Ngo A, Zaman N. Integrating artificial intelligence in orthopedic care: advancements in bone care and future directions. *Bioengineering*. 2025 May 13;12(5):513.
 27. Wu E, Huang L, Shen Y, Wei Z, Li Y, Wang J, Chen Z. Application of gelatin-based composites in bone tissue engineering. *Heliyon*. 2024 Aug 30;10(16).
 28. Khobragade SS, Deshmukh M, Vyas U, Ingle RG. Innovative approaches in bone tissue engineering: Strategies for cancer treatment and recovery. *International Journal of Molecular Sciences*. 2025 Apr 22;26(9):3937.
 29. Naz Z, Shahbaz I, Shaikh MF, Eiman U, Khan FU, Hashmi NU. Medical Management versus Surgical Decompression in lumbar Disc Herniation: outcomes Evaluation. *Indus Journal of Bioscience Research*. 2025 Nov 20;3(11):17-25.
 30. Misir A. Current developments in orthopaedic implant technology. *Journal of Orthopaedic Surgery and Research*. 2025 Oct 28;20(1):927.
 31. Cui S, Yu S, Huang HY, Lin YC, Huang Y, Zhang B, Xiao J, Zuo H, Wang J, Li Z, Li G. miRTarBase 2025: updates to the collection of experimentally validated microRNA–target interactions. *Nucleic acids research*. 2025 Jan 6;53(D1):D147-56.
 32. Mondal K, Agrawal S, Nisal A, Mondal B, Biswas P, Gupta SS. Self-Standing Macroporous 3D Scaffold from Silk Sericin: Fabrication, Characterization, and In Vitro Bio-evaluation. *New Journal of Chemistry*. 2026.
 33. Codrea CI, Fruth V. Three-Dimensionally Printed Scaffolds and Drug Delivery Systems in Treatment of Osteoporosis. *Biomimetics*. 2025 Jul 1;10(7):429.
 34. Ge Z, Xu J, Meng F, Sun M, He L, Fan Z, Du J. Peptide hydrogels for renal carcinoma therapy via synergistic inhibition of glycolysis and mitochondrial metabolism reprogramming. *ACS Applied Materials & Interfaces*. 2025 Jun 16;17(25):36487-96.

35. Grimmelpont M, Rodgers ML, Levin M, De Guise S, Agrawal A, Baron J, Bolnick DI, Milligan-McClellan K, Provas AA, Brandt JE. Temperature Modulates PFAS Accumulation and Effects on Metabolic Performance in Sheepshead Minnows. *Environmental Science & Technology*. 2026 Feb 25;60(9):6995-7010.
36. Choi H, Choi WS, Jeong JO. A review of advanced hydrogel applications for tissue engineering and drug delivery systems as biomaterials. *Gels*. 2024 Oct 25;10(11):693.
37. Shi L, Wang H, Shea GK. The application of artificial intelligence in spine surgery: a scoping review. *JAAOS Global Research & Reviews*. 2025 Apr 1;9(4):e24.
38. Wan Y, Wei W, Ding S, Wu L, Qin H, Yuan X. A multi-site synergistic effect in high-entropy alloy for efficient hydrogen evolution. *Advanced Functional Materials*. 2025 Jan;35(5):2414554.
39. Luo Y, Chen H, Chen H, Xiu P, Zeng J, Song Y, Li T. Recent advances in nanotechnology-based strategies for bone tuberculosis management. *Pharmaceutics*. 2024 Jan 29;17(2):170.
40. Shevidi S, Ghadami SA, Ghadam P, Arghand N. Inhibitory effects of silver and copper oxide nanoparticles, synthesized using *Juglans regia* green husk aqueous extract, on human insulin fibrillation. *3 Biotech*. 2025 Apr;15(4):98.
41. Chen CY, Hope Gadia Moreno RL, Wang PY, Nguyen TS, Wu JL, Chen KH, Chen CH, Lin CY, Wong PC. 3D-Printable Photothermal and Temperature-Controlled Polycaprolactone Scaffolds Incorporating Gold Plasmonic Blackbodies for Bone Tissue Engineering. *ACS Applied Materials & Interfaces*. 2025 May 13;17(20):29455-68.
42. Veg E, Raza A, Rai S, Bansal P, Sharma S, Mishra N, Gupta R, Mishra S, Joshi S, Khan AR, Khan T. Green synthesis of ZnO and α -Fe₂O₃ nanoparticles using Chinese fan palm leaf extract for their biological and photocatalytic activity evaluation. *RSC Sustainability*. 2025;3(12):5609-31.
43. Horta M, Soares P, Leite Pereira C, Lima RT. Emerging approaches in glioblastoma treatment: modulating the extracellular matrix through nanotechnology. *Pharmaceutics*. 2025 Jan 21;17(2):142.
44. Zhang H, Osama RA, Cheung R. Designing a high-efficiency graphene/black phosphorus/graphitic ZnO van der Waals heterostructure for enhanced optoelectronic performance: A first-principles study. *Computational Condensed Matter*. 2025 Oct 1;44:e01071.
45. Navazesh SE, Ji P. Iron Stress Reprograms Enterocyte Metabolism. *Metabolites*. 2025 Oct 24;15(11):691.
46. Podder D, Stala O, Hirani R, Karp AM, Etienne M. Comprehensive approaches to pain management in postoperative spinal surgery patients: advanced strategies and future directions. *Neurology international*. 2025 Jun 18;17(6):94.
47. Li Y, Xu C, Lei C. The delivery and activation of growth factors using nanomaterials for bone repair. *Pharmaceutics*. 2023 Mar;15(3):1017.
48. Ding Q, Zhang S, Liu X, Zhao Y, Yang J, Chai G, Wang N, Ma S, Liu W, Ding C. Hydrogel tissue bioengineered scaffolds in bone repair: a review. *Molecules*. 2023 Oct 12;28(20):7039.
49. Liu L, Tang H, Wang Y. Polymeric biomaterials: Advanced drug delivery systems in osteoarthritis treatment. *Heliyon*. 2023 Nov 1;9(11).
50. Liu JY, Liu XH, Zhong NN, Xiao Y, Wang GR, Liu B, Bu LL. Barriers in bone tumor treatment: the emerging role of drug delivery systems. *Medical Oncology*. 2025 Jun 28;42(8):294.